Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07214896
Enrolling by invitation Phase 2

Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings

NCT07214896 · tracked via the Priya Life Science USA tracker
Sponsor
Truway Health, Inc
Phase
Phase 2
Started
2025-10-06
Last updated
2026-11-05

Condition(s) studied

Mobility ImpairmentClinical Workflow OptimizationSanitation Protocol ComplianceESG-linked Healthcare Robotics Deployment

Investigational drug(s) / intervention(s)

Skin Cell DipStem Cell DipWage Token DistributionESG Compliance Monitoring, Operational protocol

Skin Cell Dip: Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration.

Stem Cell Dip: iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning.

Wage Token Distribution: HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion.

ESG Compliance Monitoring, Operational protocol: Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.

Study summary

This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: \- Age 18-75 years Able to provide informed consent Facility staff, clinical auditors, ESG observers, or coalition stakeholders Willing to interact with humanoid robotics in clinical workflows Available for biometric feedback and observational logging over 90 days Exclusion Criteria: \- Cognitive impairment preventing informed consent Active infectious disease requiring isolation Prior adverse reaction to biotech-enhanced robotics Involvement in conflicting clinical trials Inability to comply with protocol procedures or coalition transparency requirements

Primary outcome measure(s)

  • Biometric Audit Score ≥85 Across Five Performance Dimensions — Measured at Day 30 Post-Deployment
    This outcome assesses the performance of humanoid robotics units deployed in coalition-aligned healthcare settings. Each unit is scored across five biometric dimensions: motor function, cognitive response, ESG compliance, biotech integration, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard. Units achieving a composite score ≥85 are eligible for wage token bonuses, dip protocol expansion, and DAO-backed facility scaling.

Trial sites (4)

FacilityCityRegionStatus
Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016 New York New York
Coalition Retrofit Clinic - Austin, TX Austin Texas
ESG Compliance Lab Frankfurt Germany
Public Interface Pilot Tokyo Japan

More Truway Health, Inc. trials in the USA

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss Enrolling by invitation
TruVascular Access - Ultrasound-Guided Vascular Access Study Enrolling by invitation
A Multiphase Operational and Environmental Assessment of Lunar Surface Habitation, Lunar Gateway Transit Systems, and Acceleration Pathways for Sustained Human Habitation of the Martian Surface Enrolling by invitation
Clinical Time and Temporal Dynamics Study (CLIN-TIME) Enrolling by invitation
Truway Diagnostic Tools in Primary Care Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07214896 on ClinicalTrials.gov ↗ ← All trials in the USA